Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -21.18% is in line with its 4-year average of -22.40%, near the high end of its 4-year range (-140.05%–-6.35%).
As of the fiscal period ended Tuesday, June 30, 2026. 14.94% above its 12-month average of -24.90%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -21.18%.
RETURN ON EQUITY (ROE)
-21.18%
RETURN ON EQUITY (ROE) AVG TTM
-24.90%
RETURN ON EQUITY (ROE) AVG 3Y
-21.71%
RETURN ON EQUITY (ROE) AVG 5Y
-22.40%
RETURN ON EQUITY (ROE) AVG 10Y
-45.47%
RETURN ON EQUITY (ROE) AVG 15Y
-108.47%
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+14.94%
CURRENT VS 3Y AVG
+2.42%
CURRENT VS 5Y AVG
+5.46%
CURRENT VS 10Y AVG
+53.43%
CURRENT VS 15Y AVG
+80.47%
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 753 covered companies
CURRENT VS SECTOR MEDIAN
+49.58%
vs the sector median at left
Sunshine Biopharma, Inc.
Market Cap
$946332.00
Return on Equity (ROE)
-21.18%
TTM Avg
-24.90%
3Y Avg
-21.71%
5Y Avg
-22.40%
Market Cap
$901902.00
Return on Equity (ROE)
N/A
TTM Avg
-255.88%
3Y Avg
-273.58%
5Y Avg
-200.54%
Market Cap
$1.01M
Return on Equity (ROE)
-93.97%
TTM Avg
234.49%
3Y Avg
123.23%
5Y Avg
1171.22%
Market Cap
$868077.00
Return on Equity (ROE)
-73.66%
TTM Avg
-87.93%
3Y Avg
-127.18%
5Y Avg
-86.65%
Market Cap
$838843.00
Return on Equity (ROE)
-77.23%
TTM Avg
-124.66%
3Y Avg
-168.43%
5Y Avg
-110.88%
Market Cap
$835994.00
Return on Equity (ROE)
N/A
TTM Avg
15.66%
3Y Avg
-28.27%
5Y Avg
-26.31%
Market Cap
$824550.00
Return on Equity (ROE)
-334.41%
TTM Avg
-290.71%
3Y Avg
-280.75%
5Y Avg
-198.19%
Market Cap
$1.08M
Return on Equity (ROE)
-57.87%
TTM Avg
-222.45%
3Y Avg
-164.72%
5Y Avg
-135.78%
Market Cap
$1.12M
Return on Equity (ROE)
-200.63%
TTM Avg
-312.18%
3Y Avg
-122.70%
5Y Avg
-56.14%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Sunshine Biopharma, Inc. (SBFM) | $946332.00 | -21.18% | -24.90% | -21.71% | -22.40% |
| GlucoTrack, Inc. (GCTK)vs › | $901902.00 | N/A | -255.88% | -273.58% | -200.54% |
| Aspire Biopharma Holdings, Inc. (ASBP)vs › | $1.01M | -93.97% | 234.49% | 123.23% | 1171.22% |
| Bone Biologics Corporation (BBLG)vs › | $868077.00 | -73.66% | -87.93% | -127.18% | -86.65% |
| Bluejay Diagnostics, Inc. (BJDX)vs › | $838843.00 | -77.23% | -124.66% | -168.43% | -110.88% |
| Ridgetech, Inc. (RDGT)vs › | $835994.00 | N/A | 15.66% | -28.27% | -26.31% |
| Decoy Therapeutics Inc. (DCOY)vs › | $824550.00 | -334.41% | -290.71% | -280.75% | -198.19% |
| Clearmind Medicine Inc. (CMND)vs › | $1.08M | -57.87% | -222.45% | -164.72% | -135.78% |
| Propanc Biopharma, Inc. (PPCB)vs › | $1.12M | -200.63% | -312.18% | -122.70% | -56.14% |
| Cellyan Biotechnology Co., Ltd (HKPD)vs › | $1.13M | -11.85% | -6.20% | 47.36% | 47.36% |
ROE
-21.2%
ROA
-17.3%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -21.18% |
| 2026-03-31 | -28.07% |
| 2025-12-31 | -25.94% |
| 2025-09-30 | -24.76% |
| 2025-06-30 | -24.55% |
| 2025-03-31 | -22.16% |
| 2024-12-31 | -21.85% |
| 2024-09-30 | -16.88% |
| 2024-06-30 | -15.66% |
| 2024-03-31 | -16.47% |
| 2023-12-31 | -21.25% |
| 2023-09-30 | -121.88% |
| 2023-06-30 | -119.32% |
| 2023-03-31 | -140.05% |
| 2022-12-31 | -123.66% |
| 2022-09-30 | -6.35% |
| 2022-06-30 | -12.29% |
| 2022-03-31 | -56.24% |
| 2016-09-30 | -935.99% |
| 2013-03-31 | -906.92% |
| 2012-09-30 | -352.01% |
| 2012-06-30 | -792.64% |
| 2012-03-31 | -855.03% |
| 2011-12-31 | -538.05% |
| 2011-09-30 | -254.51% |
| 2011-06-30 | -423.18% |
| 2009-10-31 | -640.31% |
